Legal & General Group Plc Cuts Stock Position in Moderna, Inc. $MRNA

Legal & General Group Plc lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 37.2% in the second quarter, Holdings Channel reports. The firm owned 1,426,164 shares of the company’s stock after selling 845,459 shares during the period. Legal & General Group Plc’s holdings in Moderna were worth $39,348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in MRNA. Vanguard Group Inc. raised its position in Moderna by 3.2% in the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after acquiring an additional 1,312,192 shares during the period. Jump Financial LLC grew its position in shares of Moderna by 5,590.0% during the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after acquiring an additional 886,567 shares during the period. FORA Capital LLC increased its stake in shares of Moderna by 31.7% during the 1st quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock worth $2,752,000 after purchasing an additional 23,344 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after purchasing an additional 285,662 shares during the period. Finally, Letko Brosseau & Associates Inc. lifted its stake in Moderna by 2.4% in the second quarter. Letko Brosseau & Associates Inc. now owns 918,190 shares of the company’s stock valued at $25,333,000 after purchasing an additional 21,765 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MRNA. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. JPMorgan Chase & Co. cut their price target on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research note on Thursday, October 23rd. Berenberg Bank set a $28.00 price objective on Moderna in a research note on Monday, November 17th. Piper Sandler reaffirmed an “overweight” rating and set a $63.00 price objective (down from $69.00) on shares of Moderna in a report on Friday, November 21st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $29.46.

Moderna Stock Performance

NASDAQ:MRNA opened at $25.01 on Thursday. The business’s fifty day moving average is $25.88 and its 200 day moving average is $26.97. The firm has a market cap of $9.77 billion, a price-to-earnings ratio of -3.10 and a beta of 2.02. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $48.92.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($2.15) by $1.64. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The firm’s revenue was down 45.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. Equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.